Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, successfully closed its underwritten public offering of 20,010,000 shares of common stock at a price of $5.75 per share. This includes 2,610,000 additional shares issued following the full exercise of the underwriters' option to purchase extra shares. The public offering generated approximately $115.1 million in proceeds before accounting for discounts, commissions, and expenses. Joint book-running managers for the offering were Morgan Stanley, Leerink Partners, Stifel, and Cantor. Trevi is currently developing Haduvio™, an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。